The biopharmaceutical company focuses on discovering and developing antiviral programs that target respiratory viruses such as influenza, adenoviruses, rhinoviruses, and human polyomaviruses. By targeting fundamental mechanisms of viral replication, Via Nova Therapeutics aims to discover novel therapeutics for viral infections where current treatments are lacking. Their goal is to pioneer sustainable business strategies to deliver these treatments to the clinic and provide effective therapies for viral diseases arising from acute and subacute infections.